Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Average Recommendation of “Hold” from Analysts

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have received an average recommendation of “Hold” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $4.00.

Several research analysts recently issued reports on HOWL shares. Wall Street Zen upgraded shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Weiss Ratings upgraded Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 10th.

Werewolf Therapeutics Price Performance

Shares of HOWL opened at $0.92 on Wednesday. Werewolf Therapeutics has a 1-year low of $0.27 and a 1-year high of $2.13. The company has a market capitalization of $44.81 million, a P/E ratio of -1.21 and a beta of 0.51. The firm’s 50 day simple moving average is $0.76 and its 200 day simple moving average is $0.64.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Friday, July 31st. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.36. The company had revenue of $21.00 million during the quarter, compared to analysts’ expectations of $21.00 million. On average, equities analysts anticipate that Werewolf Therapeutics will post -0.89 earnings per share for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

Institutional investors have recently modified their holdings of the company. Bank of America Corp DE bought a new stake in Werewolf Therapeutics in the 2nd quarter worth approximately $112,000. Squarepoint Ops LLC bought a new position in Werewolf Therapeutics during the second quarter valued at approximately $37,000. Finally, BlackRock Inc. bought a new position in Werewolf Therapeutics during the second quarter valued at approximately $37,000. 64.84% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing investigational cancer immunotherapies. The company’s programs are designed to stimulate the immune system within the tumor microenvironment while limiting activity in healthy tissues, with the goal of improving the effectiveness and tolerability of immune-based treatments.

Werewolf’s research is based on its proprietary INDUKINE platform, which uses molecular masking and tumor-activated mechanisms to conditionally regulate immune-stimulating proteins.